DCW Ltd
DCW Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Specialty Chemicals, especially CPVC and SIOP segments, are expected to be the backbone of growth with volume increases from new capacities. DCW Limited expects gradual recovery and improvement in earnings with positive outlook for FY26 amid improving global market conditions. - Specialty chemicals segment, especially CPVC and SIOP, is the primary growth driver, showing volume growth and margin stability. - EBITDA margins anticipated to be sustainable in the 30%-35% range for SIOP segment over next two years. - Synthetic rutile business expected to improve with margins returning to historic levels north of 20%. - Margin expansion seen through operational efficiencies, cost savings from renewable power projects, and capacity expansions. - Debt reduction is a critical focus; scheduled repayments of Rs.
From DCW Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty Chemicals, especially CPVC and SIOP segments, are expected to be the backbone of growth with volume increases from new capacities.
- CPVC capacity expansion from 20,000 to 50,000 tons planned, with market demand supportive for increased sales.
- SIOP segment aims to maintain stable margins of 30%-35% and increase volumes, including new micronized products that command higher prices.
- Export markets, particularly the US, are stable with potential volume increases due to long-term customer ties.
- Synthetic rutile sales have started recovering with positive volume traction.
- Overall capacity utilization improved to above 80%; full utilization expected to drive revenue growth.
2 more points from DCW Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what DCW Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX includes Rs. 140 crores for CPVC capacity expansion from 20,000 TPA to 50,000 TPA and debottlenecking of SIOP.
- Previous CAPEX of around Rs. 125 crores aimed at doubling CPVC capacity from 10,000 to 20,000 TPA and debottlenecking SIOP.
- Micronization plant for SIOP is planned, aimed at product quality and volume growth; specific CAPEX details not provided yet.
- Alternative energy project nearing completion with first phase operational soon, expected to bring cost efficiencies.
- No current strategic partnerships or acquisitions; evaluation ongoing but expansions announced keep focus until next year.
2 more points from DCW Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what DCW Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is no specific mention of the current or expected order book or pending orders in the provided transcript.
- The company highlighted securing long-term contracts, especially for synthetic rutile and CPVC products.
- They emphasized a gradual recovery in demand rather than a V-shaped rebound.
- CPVC volumes are expected to increase with the ongoing expansion, indicating future order fulfillment.
2 more points from DCW Ltd's call on order book
Pro opens every point from 15K+ earnings calls
DCW Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹609 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What DCW's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Himadri Special (Q3 FY25)
1,131.81 Crs, up 7.53% YoY (from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Gujarat Alkalies (Q3 FY25)
3,702.77 Crores (up from Rs. Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- Balaji Amines (Q3 FY25)
Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Key concall takeaways from Balaji Amines Ltd's Q3…
- Vidhi Specialty (Q3 FY25)
Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 earnings call — and how it ranks…
Arthneeti Pro · Annual
DCW Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were DCW Ltd Q3 FY25 results?
Specialty Chemicals, especially CPVC and SIOP segments, are expected to be the backbone of growth with volume increases from new capacities. DCW Limited expects gradual recovery and improvement in earnings with positive outlook for FY26 amid improving global market conditions. - Specialty chemicals segment, especially CPVC and SIOP, is the primary growth driver, showing volume growth and margin stability. - EBITDA margins anticipated to be sustainable in the 30%-35% range for SIOP segment over next two years. - Synthetic rutile business expected to improve with margins returning to historic levels north of 20%. - Margin expansion seen through operational efficiencies, cost savings from renewable power projects, and capacity expansions. - Debt reduction is a critical focus; scheduled repayments of Rs.
What is DCW Ltd share price analysis?
DCW Ltd currently shows a neutral. The stock trades at a P/E of 18.2 with a market cap of ₹1,300 Cr. Investors should review the full earnings analysis for detailed insights.
Is DCW Ltd planning capital expenditure?
Current CAPEX includes Rs.
Keep DCW Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.